Opinion
A PhD candidate in clinical psychology, Josh Lipson, reflects on the perception of psychedelics after the FDA decision, their role in meaning-making and enchantment, and the importance of the sacred frame.
As we approach the end of a year where funding has been tight, consider donating to a nonprofit organization that supports psychedelic healing, education and culture.
Massachusetts voter Scott Edward Anderson reflects on why Ballot Question 4, the Legalization and Regulation of Psychedelic Substances Initiative, failed to pass — and what’s next.
A minister explores the spiritual and communal dimensions of psychedelics as sacred sacraments, offering a transformative alternative to clinical frameworks.
Therapist Charles Wininger offers an elder’s perspective on how to approach the election and its aftermath from a psychedelic point of view.
Beatriz Labate, Ph.D and Henrique Antunes, Ph.D. offer insights into critical dialogues about psychedelics between the Global North and Global South and diverging perspectives on the “Psychedelic Renaissance.”
Bay State author and psychedelic-assisted therapy advocate Scott Edward Anderson argues that Ballot Measure 4 establishes new models that prioritize healing, innovation, and compassion.
In part one of a series of articles on ibogaine clinics, researcher Leonard Pickard looks at the history and treatment protocols of clinics in Mexico, Brazil and Portugal.
Elizabeth Nielson, co-founder of Fluence, offers thoughts on the roll out of the 2025 psychedelic therapy program in Colorado and the opportunities it offers for mental health professionals.
In the wake of the FDA’s rejection of Lykos Therapeutics’ proposal for MDMA-Assisted therapy for PTSD, a therapist advocates for wider access to ketamine-assisted psychotherapy.
